Brought to you by 
Lexicon Genetics, BMS in neuroscience drug development deal
15 Apr 2015
Executive Summary
Bristol-Myers Squibb and Lexicon Genetics (knock-out technology to identify roles of disease-causing genes in murine models) are launching a joint effort in medicinal chemistry and preclinical development to discover, develop, and market small-molecule drugs for targets in the areas of depression, anxiety, schizophrenia, pain, and Alzheimer's disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lexicon Genetics, BMS in neuroscience drug development deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice